SREBF1 and steatosis: Therefore, researchers consider the LXRα/SREBP-1c pathway an attractive target for the prevention and/or treatment of steatosis in hepatocytes [33], and several lines of evidence indicate that the suppression or disruption of LXRα leads to the reduction of hepatic triglyceride synthesis and accumulation [12, 34].